We are live on !
Find out more
Sofinnova Investments Portfolio holdings
AUM
$1.93B
Turnover
49.43%
1-Year Est. Return
134.74%
This Fund
S&P 500
This Quarter Est. Return
+23%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
-$697M
(-26%)
Cap. Flow
-$415M
Cap. Flow % of AUM
Cap. Flow %
-21.46%
Top 10 Holdings %
Top 10 Hldgs %
57.89%
Holding
87
New
13
Increased
14
Reduced
17
Closed
30
Avg Time Held
Equity + Options
1.5
years
Top 10 Avg Time Held
Equity + Options
1.3
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1.6
years
Top 10 Avg Time Held Equity only
1.4
years
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genmab
GMAB
|
+$87.5M |
| 2 |
Seaport Therapeutics
SPTX
|
+$62.7M |
| 3 |
Gilead Sciences
GILD
|
+$45.2M |
| 4 |
AnaptysBio
ANAB
|
+$14.9M |
| 5 |
Abbott
ABT
|
+$11.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$89.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$63.8M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
+$51M |
| 4 |
United Therapeutics
UTHR
|
+$47.1M |
| 5 |
Biogen
BIIB
|
+$42.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.78% |
| 2 | Miscellaneous | 3.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Natera
NTRA
$58.4B
| $421M | 21.76% |
1,550,280
| – | – |
2018 Q1
33 quarters
|
|
2
Vera Therapeutics
VERA
$2.04B
| $120M | 6.2% |
2,793,987
| – | – |
2021 Q2
20 quarters
|
|
|
3
Genmab
GMAB
$27.5B
| $111M | 5.74% |
4,045,215
+3,292,954
| +438% | +$87.5M |
2026 Q1
1 quarter
|
|
|
4
Jazz Pharmaceuticals
JAZZ
$13.4B
| $88M | 4.55% |
365,341
-232,986
| -39% | -$51M |
2024 Q3
7 quarters
|
|
5
Rapport Therapeutics
RAPP
$1.22B
| $79.4M | 4.1% |
1,904,408
| – | – |
2024 Q2
8 quarters
|
|
|
6
Seaport Therapeutics
SPTX
$1.12B
| $77.4M | 4% |
+3,564,871
| New | +$62.7M |
2026 Q2
0 quarters
|
|
7
ArriVent BioPharma
AVBP
$757M
| $58.9M | 3.05% |
1,696,752
| – | – |
2024 Q1
9 quarters
|
|
8
Ultragenyx Pharmaceutical
RARE
$1.59B
| $57.3M | 2.96% |
1,717,505
-1,428,383
| -45% | -$35.5M |
2025 Q4
2 quarters
|
|
9
BioAge Labs
BIOA
$229M
| $56.2M | 2.91% |
2,293,788
| – | – |
2024 Q3
7 quarters
|
|
|
10
Bristol-Myers Squibb
BMY
$126B
| $50.5M | 2.61% |
876,970
-1,111,751
| -56% | -$63.8M |
2025 Q4
2 quarters
|
|
11
Supernus Pharmaceuticals
SUPN
$2.37B
| $48.2M | 2.49% |
1,036,328
+82,019
| +9% | +$3.94M |
2025 Q1
5 quarters
|
|
12
Rhythm Pharmaceuticals
RYTM
$6.16B
| $45.3M | 2.34% |
408,027
-42,069
| -9% | -$3.8M |
2024 Q3
7 quarters
|
|
|
13
Gilead Sciences
GILD
$197B
| $43.3M | 2.24% |
+343,100
| New | +$45.2M |
2026 Q2
0 quarters
|
|
|
14
United Therapeutics
UTHR
$25.4B
| $41.4M | 2.14% |
76,489
-83,581
| -52% | -$47.1M |
2025 Q2
4 quarters
|
|
15
Cogent Biosciences
COGT
$5.36B
| $40.1M | 2.07% |
1,035,148
-1,078,403
| -51% | -$37.7M |
2024 Q1
9 quarters
|
|
16
Axsome Therapeutics
AXSM
$7.55B
| $39.3M | 2.03% |
160,429
-52,318
| -25% | -$11.3M |
2024 Q2
8 quarters
|
|
17
Immatics
IMTX
$1.09B
| $37.2M | 1.92% |
3,669,346
+38,892
| +1% | +$411K |
2020 Q3
23 quarters
|
|
18
Dyne Therapeutics
DYN
$2.94B
| $36.8M | 1.9% |
1,658,384
+24,487
| +1% | +$455K |
2023 Q2
12 quarters
|
|
19
Immunome
IMNM
$2.11B
| $36.5M | 1.88% |
1,720,316
+18,412
| +1% | +$394K |
2024 Q1
9 quarters
|
|
20
IDEAYA Biosciences
IDYA
$3.17B
| $34.5M | 1.78% |
925,119
-206,667
| -18% | -$6.33M |
2022 Q3
15 quarters
|
|
|
21
AnaptysBio
ANAB
$1.46B
| $33.3M | 1.72% |
493,536
+245,283
| +99% | +$14.9M |
2024 Q4
6 quarters
|
|
22
Nektar Therapeutics
NKTR
$1.28B
| $32.9M | 1.7% |
471,763
-37,783
| -7% | -$2.76M |
2025 Q3
3 quarters
|
|
23
Pharvaris
PHVS
$2.21B
| $30.5M | 1.58% |
881,299
+62,971
| +8% | +$1.91M |
2023 Q4
10 quarters
|
|
24
Arcus Biosciences
RCUS
$2.26B
| $29.2M | 1.51% |
945,690
+22,604
| +2% | +$559K |
2025 Q1
5 quarters
|
|
25
Inhibrx
INBX
$1.3B
| $28.7M | 1.48% |
303,103
-102,926
| -25% | -$10.3M |
2024 Q2
8 quarters
|
|
Similar funds
TCM
Sofinnova Investments's Q2 2026 Portfolio in Review
As of Q2 2026, Sofinnova Investments held 87 positions worth $1.93B, down 26% from $2.63B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Sofinnova Investments withdrew a net $415M in Q2 2026, closing 30 positions and reducing 17 holdings. Its most notable exit was AstraZeneca, an estimated $89.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 76% a quarter earlier, followed by Miscellaneous.
Against the trend, Sofinnova Investments opened a new position in Seaport Therapeutics worth $77.4M.
- Sofinnova Investments's largest Q2 2026 buy was Seaport Therapeutics: 3,564,871 shares worth $77.4M.
- Sofinnova Investments added most to Genmab in Q2 2026, an estimated $87.5M increase.
- Sofinnova Investments's biggest Q2 2026 reduction was Bristol-Myers Squibb, cutting an estimated $63.8M.
- Sofinnova Investments fully exited AstraZeneca in Q2 2026, selling an estimated $89.9M.
- Sofinnova Investments's ten largest holdings make up 58% of its $1.93B portfolio in Q2 2026.
- Sofinnova Investments opened 13 new positions and closed 30 in Q2 2026.
- Sofinnova Investments's portfolio value fell 26% quarter-over-quarter to $1.93B.
Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.